London (UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces its Chief Executive Officer Max Herzberg will present new insights in the development of Vidac’s two drug candidates - VDA-1102 against actinic keratosis (AK) and cutaneous T-cell lymphoma (CTCL) and VDA-1275 against solid tumors - at the 5th Annual European Healthtech CEO Forum in Zurich.
“Vidac Pharma’s non-toxic drug candidates are attacking cancer at its core, reversing the abnormal metabolism that is common to all cancer cells. This halts cancer cell proliferation, restores immune-sensitivity, and switches programmed cell death back on. Clinical results so far are very encouraging, and I am looking forward to engage in discussions about the advancement of our pioneering drug candidates at the Sachs Forum, an excellent platform to meet industry peers and investors,” Vidac Pharma Chief Executive Officer Max Herzberg said.
Vidac Pharma’s family of small molecules prevents the Hexokinase 2 (HK2) enzyme from blocking the VDAC mitochondrial relay channels, reinstalling apoptosis (programmed cell death), and starving cancer cells of the special fuel they derive from their glycolytic metabolism. Last month, the company reported interim Phase 2a results for VDA-1102 in CTCL that compared favorably to the standard of care. Vidac is about to launch a Phase 2b study for VDA-1102 for AK, the other indication for this drug candidate, selecting patients with an advanced stage of the disease, in which VDA-1102 has shown to be more effective. Its other candidate VDA-1275 is in the preclinical stage for a wide range of solid tumors.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK) and is also being tested in Cutaneous T-cell Lymphoma (CTCL) in Phase 2 trials in humans.
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.